StockNews.com lowered shares of Greenlight Capital Re (NASDAQ:GLRE – Free Report) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.
Greenlight Capital Re Stock Up 1.5 %
NASDAQ GLRE opened at $14.13 on Wednesday. The stock has a fifty day moving average of $14.42 and a 200-day moving average of $13.77. The stock has a market capitalization of $492.18 million, a P/E ratio of 5.61 and a beta of 0.89. Greenlight Capital Re has a 52 week low of $10.95 and a 52 week high of $15.82. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.02 and a current ratio of 3.02.
Greenlight Capital Re (NASDAQ:GLRE – Get Free Report) last released its earnings results on Monday, November 4th. The financial services provider reported $1.01 EPS for the quarter, beating the consensus estimate of $0.65 by $0.36. The company had revenue of $188.01 million during the quarter. Greenlight Capital Re had a return on equity of 13.95% and a net margin of 12.38%. During the same period last year, the business posted $0.39 earnings per share.
Institutional Inflows and Outflows
Greenlight Capital Re Company Profile
Greenlight Capital Re, Ltd., through its subsidiaries, operates as a property and casualty reinsurance company worldwide. The company offers various property reinsurance products and services, including automobile physical damage, personal lines, and commercial lines. It also provides casualty reinsurance products and services comprising general liability, motor liability, professional liability, and worker's compensation; and accident and health, transactional liability, mortgage insurance, surety, trade credit, marine, and energy, as well as other specialty products, such as aviation, crop, cyber, political, and terrorism products.
Featured Stories
- Five stocks we like better than Greenlight Capital Re
- Upcoming IPO Stock Lockup Period, Explained
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Where to Find Earnings Call Transcripts
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
- Find and Profitably Trade Stocks at 52-Week Lows
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
Receive News & Ratings for Greenlight Capital Re Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenlight Capital Re and related companies with MarketBeat.com's FREE daily email newsletter.